GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » Days Sales Outstanding

Emmaus Life Sciences (Emmaus Life Sciences) Days Sales Outstanding : 92.38 (As of Sep. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences Days Sales Outstanding?

Emmaus Life Sciences's average Accounts Receivable for the three months ended in Sep. 2023 was $5.08 Mil. Emmaus Life Sciences's Revenue for the three months ended in Sep. 2023 was $5.02 Mil. Hence, Emmaus Life Sciences's Days Sales Outstanding for the three months ended in Sep. 2023 was 92.38.

The historical rank and industry rank for Emmaus Life Sciences's Days Sales Outstanding or its related term are showing as below:

EMMA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 9.71   Med: 18.13   Max: 54.33
Current: 36.5

During the past 13 years, Emmaus Life Sciences's highest Days Sales Outstanding was 54.33. The lowest was 9.71. And the median was 18.13.

EMMA's Days Sales Outstanding is ranked better than
80.31% of 889 companies
in the Biotechnology industry
Industry Median: 71.97 vs EMMA: 36.50

Emmaus Life Sciences's Days Sales Outstanding increased from Sep. 2022 (25.18) to Sep. 2023 (92.38).


Emmaus Life Sciences Days Sales Outstanding Historical Data

The historical data trend for Emmaus Life Sciences's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emmaus Life Sciences Days Sales Outstanding Chart

Emmaus Life Sciences Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.71 17.75 18.50 10.96 14.04

Emmaus Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.18 14.36 17.42 32.98 92.38

Competitive Comparison of Emmaus Life Sciences's Days Sales Outstanding

For the Biotechnology subindustry, Emmaus Life Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emmaus Life Sciences's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Days Sales Outstanding falls into.



Emmaus Life Sciences Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Emmaus Life Sciences's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

Days Sales Outstanding (A: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( (1.04 + 0.375) / 2 ) / 18.39*365
=0.7075 / 18.39*365
=14.04

Emmaus Life Sciences's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding (Q: Sep. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Sep. 2023 )) / count ) / Revenue (A: Sep. 2023 )*Days in Period
=( (5.573 + 4.587) / 2 ) / 5.018*365 / 4
=5.08 / 5.018*365 / 4
=92.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Emmaus Life Sciences  (OTCPK:EMMA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Emmaus Life Sciences Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.
Executives
Seah H. Lim director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee director, officer: Vice Chairman & COO 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara director, 10 percent owner, officer: Chairman and CEO 20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi director 1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark officer: SVP, Clinical Development 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich officer: CIO & SVP 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood director 956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen director 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii officer: Chief Financial Officer 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato director 3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker director 21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran officer: Chief Administrative Officer 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey director 320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki officer: Sr. VP Finance 20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501